CClinicalTrials.gg
CompletedNCT02022488Updated Dec 30, 2013

Sevoflurane Induced Emergence Agitation

A Phase 4 interventional study of midazolam and alfentanil in Emergence Agitation, sponsored by Yeditepe University Hospital. Completed at 1 site in Turkey. Open to participants aged 1 Year to 8 Years. Per ClinicalTrials.gov, last updated 2013-12-30.

Sponsored by Yeditepe University Hospital · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
1 Year to 8 Years
Sex
All
01

Study summary

Investigators evaluated the effect of intranasal ketamine or alfentanil addition to oral midazolam for prevention of emergence agitation.Seventy-eight, 1-8 year-old children, undergoing urological surgery with sevoflurane anesthesia was included in the study. All the children received oral midazolam 0.5 mg/kg 40 minutes before anesthesia induction then enrolled to one of the study groups, randomly. Ketamine group (Group MK; n=26) patients were given 2mg/kg intranasal ketamine whereas, alfentanil group (Group MA; n=25) were given 10microgram/kg intranasal alfentanil 8-10 min before the induction of anesthesia. Saline group (Group MS; n=27) received intranasal isotonic saline.Parental separation, mask acceptance were evaluated with a 4- point scale. Emergence agitation was evaluated with Pediatric Anesthesia Emergence Delirium score.

02

Conditions studied

  • Emergence Agitation

Keywords

  • Child
  • Sevoflurane
  • Emergence delirium
  • General anesthesia
  • Premedication.
03

In context

Psychomotor Agitation

500 studies on the registry are indexed under Psychomotor Agitation; 55 are open to participants now.

This study's enrollment of 78 is below the median of 90 across 413 interventional studies indexed under Psychomotor Agitation.

Browse Psychomotor Agitation studies →

Lead sponsor

Yeditepe University Hospital is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 1- 8 years
  • American Society of Anesthesiologist (ASA) I-II,
  • Patients undergoing procedures below the umbilicus

Exclusion criteria

Exclusion Criteria:

  • cardiac diseases
  • pulmonary diseases
  • hepatic diseases
  • renal diseases
  • psychological or emotional disorders
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Active comparator
    midazolam and alfentanil

    Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)

    Drug: midazolam · Drug: alfentanil

  • Active comparator
    midazolam and ketamine

    Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)

    Drug: midazolam · Drug: ketamine

  • Placebo comparator
    midazolam

    Midazolam 0.5mg/kg

    Drug: midazolam

Interventions

  • Drugmidazolam

    Group M

  • Drugalfentanil

    Group MA

  • Drugketamine

    Group MK

06

What researchers measure

Primary outcomes

  1. Pediatric Anesthesia Emergence Delirium (PAED) score

    Emergence agitation was evaluated using the Pediatric Anesthesia Emergence Delirium (PAED) score

    Time frame: 7 months

Secondary outcomes

  1. Parental separation score

    Parental separation were evaluated with a 4- point scale in the preoperative period

    Time frame: 7 months

  2. Mask acceptance

    The ease of mask acceptance were evaluated with a 4- point scale in the preoperative period

    Time frame: 7 months

07

Study locations

1 site
  • Yeditepe University Hospital
    Istanbul, 34752, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02022488
Lead sponsor
Yeditepe University Hospital
Responsible party
Sevgi Bilgen (Yeditepe University, Yeditepe University Hospital) — Principal investigator
First posted
Dec 27, 2013
Start date
Feb 2012
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Dec 30, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion